We heard some great news: Pfizer and BioNTech have partnered with the Biovac Institute in Cape Town to manufacture and distribute 100 million doses of the vaccine to the African Union’s 55 member states, annually. “Biovac will obtain the drug substance from facilities in Europe, and manufacturing of finished doses will begin in 2022,” the companies said in a joint statement. This is a huge win given ongoing vaccine apartheid and hoarding by developed countries. The news also follows last week’s announcement that will see Johnson & Johnson vaccines manufactured and distributed under licence in South Africa. If you haven’t noticed, South Africa is becoming an African pioneer when it comes to ensuring vaccine equality on the continent. This is something we love to see! 😁
As far as vaccine rollout is concerned, we’re doing much better than before. In recent days more than 230 000 people have been vaccinated on a single day. The spike (ha!) comes as more age groups are incorporated into the rollout. Last week, people over the age of 35 began registering to get their shot and you’ve PROBABLY heard by now how enthusiastic that elderly millennial cohort is about the whole thing. 😂 This will hopefully put us back on track to reach our target to achieve herd immunity by 2022. So keep at it, y’all! By the way, the third wave is still in our midst, but things are beginning to slowly simmer down.